keyword
https://read.qxmd.com/read/38675125/antiviral-effect-of-antimicrobial-peptoid-tm9-and-murine-model-of-respiratory-coronavirus-infection
#41
JOURNAL ARTICLE
Maxim Lebedev, Aaron B Benjamin, Sathish Kumar, Natalia Molchanova, Jennifer S Lin, Kent J Koster, Julian L Leibowitz, Annelise E Barron, Jeffrey D Cirillo
New antiviral agents are essential to improving treatment and control of SARS-CoV-2 infections that can lead to the disease COVID-19. Antimicrobial peptoids are sequence-specific oligo- N -substituted glycine peptidomimetics that emulate the structure and function of natural antimicrobial peptides but are resistant to proteases. We demonstrate antiviral activity of a new peptoid (TM9) against the coronavirus, murine hepatitis virus (MHV), as a closely related model for the structure and antiviral susceptibility profile of SARS-CoV-2...
March 27, 2024: Pharmaceutics
https://read.qxmd.com/read/38674610/a-retrospective-analysis-of-systemic-bartonella-henselae-infection-in-children
#42
JOURNAL ARTICLE
Ramona Florina Stroescu, Flavia Chisavu, Ruxandra Maria Steflea, Gabriela Doros, Teofana-Otilia Bizerea-Moga, Dan Dumitru Vulcanescu, Teodora Daniela Marti, Casiana Boru, Cecilia Roberta Avram, Mihai Gafencu
Systemic Bartonella henselae infection, also known as cat-scratch disease (CSD), presents a diagnostic challenge due to the variability of clinical manifestations and the potential for serological cross-reactivity with other organisms. This study aimed to retrospectively analyze the epidemiological, clinical, laboratory, and imaging characteristics of pediatric patients diagnosed with systemic B. henselae infection, to improve understanding and facilitate timely diagnosis and treatment. We conducted a 10-year retrospective study at the "Louis Turcanu" Children's Emergency Hospital and private clinics in Timisoara, Romania, reviewing records for confirmed cases of B...
March 27, 2024: Microorganisms
https://read.qxmd.com/read/38674122/nlrp3-inflammasome-in-acute-and-chronic-liver-diseases
#43
REVIEW
Katia Sayaf, Sara Battistella, Francesco Paolo Russo
NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) is an intracellular complex that upon external stimuli or contact with specific ligands, recruits other components, forming the NLRP3 inflammasome. The NLRP3 inflammasome mainly mediates pyroptosis, a highly inflammatory mode of regulated cell death, as well as IL-18 and IL-1β production. Acute and chronic liver diseases are characterized by a massive influx of pro-inflammatory stimuli enriched in reactive oxygen species (ROS) and damage-associated molecular patterns (DAMPs) that promote the assemblage and activation of the NLRP3 inflammasome...
April 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38673017/factors-positively-correlated-with-hepatitis-b-surface-antigen-seroconversion-in-chronic-hepatitis-b
#44
JOURNAL ARTICLE
Matthias Buechter, Arne Maria Günther, Paul Manka, Guido Gerken, Alisan Kahraman
BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV) infection is a global public health challenge since more than 250 million individuals are affected worldwide. Since different treatment modalities are available and not all patients are candidates for antiviral treatment, biomarkers that potentially predict the possibility of HBsAg clearance and seroconversion may be useful in clinical practice. PATIENTS AND METHODS: In this retrospective study, we aimed to identify factors positively correlated with HBsAg seroconversion in a large cohort of 371 chronic hepatitis B patients treated at a German tertial center between 2005 and 2020...
April 5, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38672991/longterm-outcome-of-therapeutic-vaccination-with-a-third-generation-pre-s-s-hbv-vaccine-prehevbrio-r-of-chronically-hbv-infected-patients
#45
JOURNAL ARTICLE
Hedwig Roggendorf, Daniel Shouval, Michael Roggendorf, Guido Gerken
Several antiviral treatment regimens for chronic hepatitis B (CHB) virus infection have been shown to be effective in suppressing viral load and reducing the risk of hepatocellular injury and its complications. It has been hypothesized that high levels of circulating HBV surface antigen(s) may lead to immune tolerance against HBV and contribute to chronic carriership. Conversely, low-level HBsAg may create a window for the reconstitution of an HBV-specific immune response through vaccination and control of infection...
March 29, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38672687/seroprevalence-of-sars-cov-2-and-hepatitis-b-virus-coinfections-among-ethiopians-with-acute-leukemia
#46
JOURNAL ARTICLE
Jemal Alemu, Balako Gumi, Aster Tsegaye, Ziyada Rahimeto, Dessalegn Fentahun, Fozia Ibrahim, Abdulaziz Abubeker, Amha Gebremedhin, Tesfaye Gelanew, Rawleigh Howe
SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021...
April 22, 2024: Cancers
https://read.qxmd.com/read/38672595/time-restricted-feeding-attenuates-metabolic-dysfunction-associated-steatohepatitis-and-hepatocellular-carcinoma-in-obese-male-mice
#47
JOURNAL ARTICLE
Manasi Das, Deepak Kumar, Consuelo Sauceda, Alexis Oberg, Lesley G Ellies, Liping Zeng, Lily J Jih, Isabel G Newton, Nicholas J G Webster
Metabolic dysfunction-associated steatotic liver disease (MASLD) has surpassed the hepatitis B virus and hepatitis C virus as the leading cause of chronic liver disease in most parts of the Western world. MASLD (formerly known as NAFLD) encompasses both simple steatosis and more aggressive metabolic dysfunction-associated steatohepatitis (MASH), which is accompanied by inflammation, fibrosis, and cirrhosis, and ultimately can lead to hepatocellular carcinoma (HCC). There are currently very few approved therapies for MASH...
April 16, 2024: Cancers
https://read.qxmd.com/read/38672587/the-role-of-hepatitis-viruses-as-drivers-of-hepatocancerogenesis
#48
REVIEW
Mario Capasso, Valentina Cossiga, Maria Guarino, Luisa Ranieri, Filomena Morisco
Recently, metabolic associated steatotic liver disease (MASLD) became the leading cause of chronic liver disease worldwide and one of the most frequent causes of hepatocellular carcinoma (HCC). Nonetheless, in this epidemiological trend, viral hepatitis remains the major driver in hepatic carcinogenesis. Globally, hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma, with an overall attributable risk of approximately 40%, followed by hepatitis C virus (HCV), which accounts for 28-30% of cases, with significant geographic variations between the Eastern and Western world...
April 15, 2024: Cancers
https://read.qxmd.com/read/38670855/challenges-and-facilitators-in-repeated-bio-behavioural-surveys-for-blood-borne-virus-infections-in-australian-prisons
#49
JOURNAL ARTICLE
Rugi Bah, Yumi Sheehan, Xiaoying Li, Nicola Price, Tony Butler, Gregory J Dore, Jason Grebely, Andrew R Lloyd, Behzad Hajarizadeh
BACKGROUND: Prison-based blood-borne virus (BBV) surveillance is essential for evaluation of prevention and treatment programs for high-risk populations, such as people who inject drugs who are over-represented amongst those incarcerated. Regular triennial surveillance has been in place in Australian prisons for almost two decades, but has been focused to date only on new prison entrants. Recently, the Australian Hepatitis and risk survey in prisons (AusHep study) was established to provide improved surveillance via an expanded bio-behavioural survey representative of all people in prison, including those sentenced and those on remand...
April 25, 2024: International Journal on Drug Policy
https://read.qxmd.com/read/38670853/hepatitis-b-virus-core-protein-as-a-rab-gap-suppressor-driving-liver-disease-progression
#50
JOURNAL ARTICLE
Yu Su, Fan Bu, Yuanfei Zhu, Le Yang, Qiong Wu, Yuan Zheng, Jianjin Zhao, Lin Yu, Nan Jiang, Yongxiang Wang, Jian Wu, Youhua Xie, Xinxin Zhang, Yueqiu Gao, Ke Lan, Qiang Deng
Chronic hepatitis B virus (HBV) infection can lead to advanced liver pathology. Here, we establish a transgenic murine model expressing a basic core promoter (BCP)-mutated HBV genome. Unlike previous studies on the wild-type virus, the BCP-mutated HBV transgenic mice manifest chronic liver injury that culminates in cirrhosis and tumor development with age. Notably, agonistic anti-Fas treatment induces fulminant hepatitis in these mice even at a negligible dose. As the BCP mutant exhibits a striking increase in HBV core protein (HBc) expression, we posit that HBc is actively involved in hepatocellular injury...
April 8, 2024: Science Bulletin
https://read.qxmd.com/read/38670168/seroprevalence-of-anti-sars-cov-2-in-patients-with-hepatitis-b-and-c-a-pre-vaccination-study
#51
JOURNAL ARTICLE
Lucas Lima da Silva, Lia Laura Lewis-Ximenez, Monica Magalhaes Figueiredo, Vanessa Salete de Paula, Livia Melo Villar
The serological markers for the diagnosis of COVID-19 plays an important role in the epidemiological investigation of the pandemic. This study aims to assess the prevalence of anti-SARS-CoV-2 in hepatitis B and C patients in a pre-vaccination of COVID-19 period. Between March 2020 and January 2021, 199 serum samples from individuals with HBsAg/HBV DNA or anti-HCV/HCV RNA positivity were tested for antibodies (IgM and IgG) against SARS-CoV-2 using Electrochemiluminescent Immunoassay (ECLIA). Among these, 50...
April 23, 2024: Brazilian Journal of Infectious Diseases
https://read.qxmd.com/read/38669827/potential-role-of-vitamin-d-in-immune-response-in-patients-with-viral-hepatitis
#52
JOURNAL ARTICLE
Catharina Gerhards, Andreas Teufel, Marlis Gerigk, Michael French, Christoph Antoni, Matthias Ebert, Michael Neumaier, Osman Evliyaoglu
BACKGROUND: To study the relationship of Vitamin D with innate and adaptive immune response parameters in chronic hepatitis B and C patients. METHODS: The laboratory data between January 1, 2013 and February 1, 2023, for patients with chronic hepatitis B (CHB), and chronic hepatitis C (CHC) were extracted. Serum 25-hydroxyl vitamin D, hepatitis B virus serological markers, complements, and subsets of T lymphocytes were determined. Study cohorts were divided into groups based on serum 25-hydroxyl vitamin D levels with further evaluation of laboratory data...
March 30, 2024: Nutrition
https://read.qxmd.com/read/38669259/a-hepatitis-b-virus-hbv-sequence-variation-graph-improves-alignment-and-sample-specific-consensus-sequence-construction
#53
JOURNAL ARTICLE
Dylan Duchen, Steven J Clipman, Candelaria Vergara, Chloe L Thio, David L Thomas, Priya Duggal, Genevieve L Wojcik
Nearly 300 million individuals live with chronic hepatitis B virus (HBV) infection (CHB), for which no curative therapy is available. As viral diversity is associated with pathogenesis and immunological control of infection, improved methods to characterize this diversity could aid drug development efforts. Conventionally, viral sequencing data are mapped/aligned to a reference genome, and only the aligned sequences are retained for analysis. Thus, reference selection is critical, yet selecting the most representative reference a priori remains difficult...
2024: PloS One
https://read.qxmd.com/read/38668276/hepatitis-c-prevalence-and-birth-outcomes-among-pregnant-women-in-the-united-states-a-2010-2020-population-study
#54
JOURNAL ARTICLE
Paul Wasuwanich, Songyos Rajborirug, Robert S Egerman, Tony S Wen, Wikrom Karnsakul
BACKGROUND: The rates of hepatitis C virus (HCV) infection have increased in the pregnant population. We aim to describe the age-stratified clinical outcomes and trends for inpatient pregnant women with HCV in the U.S. METHODS: We utilized hospitalization data from the 2010-2020 National Inpatient Sample. Pregnancy and HCV were identified according to their ICD-9/ICD-10 codes. Demographic and clinical data including cirrhosis, mortality, preterm birth, and stillbirth were extracted...
April 14, 2024: Pathogens
https://read.qxmd.com/read/38668246/prospects-for-controlling-hepatitis-b-globally
#55
REVIEW
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer. Although protective HBV vaccines are recommended for all newborns, global coverage is suboptimal. In adults, sexual transmission is by far the most frequent route of contagion. The WHO estimates that 1.5 million new HBV infections occur annually. Oral nucleos(t)ide analogues entecavir and tenofovir are the most frequent antivirals prescribed as HBV therapy...
March 29, 2024: Pathogens
https://read.qxmd.com/read/38668009/knowledge-attitudes-and-practices-of-dental-students-from-romania-regarding-self-perceived-risk-and-prevention-of-infectious-diseases
#56
JOURNAL ARTICLE
Florentina Iuliana Dincă, Bogdan-Alexandru Dimitriu, Oana Săndulescu, Valentin Daniel Sîrbu, Mihai Săndulescu
University education is a leading source of information for dental practitioners. Particular emphasis should be given to determining the extent to which students acquire positive knowledge, attitudes, and practices (KAP) and positive metacompetences beyond the scope of each studied dental discipline. We performed a cross-sectional questionnaire-based study among dentistry students from Romania to assess self-perceived risk of infectious diseases and their KAP on topics related to infectious disease prevention...
April 10, 2024: Dentistry Journal
https://read.qxmd.com/read/38663455/interim-analysis-of-the-paradise-study-benefits-of-add-on-peginterferon-%C3%AE-in-na-treated-patients-with-chb
#57
JOURNAL ARTICLE
Shaowen Jiang, Simin Guo, Yan Huang, Jie Xu, Yi Li, Yilan Zeng, Yuan Guo, Lijuan Ouyang, Chuanwu Zhu, Weifeng Zhao, Qin Zhang, Qing Guo, Haiguang Xin, Qing Xie
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monotherapy...
April 23, 2024: Antiviral Research
https://read.qxmd.com/read/38663255/synthesis-and-evaluation-of-pentacyclic-triterpenoids-conjugates-as-novel-hbv-entry-inhibitors-targeting-ntcp-receptor
#58
JOURNAL ARTICLE
Yixin Chen, Meitao Duan, Xiangwan Wang, Jianling Xu, Shuo Tian, Xiaotian Xu, Ao Duan, Ahmed Mahal, Yongyan Zhu, Quanhong Zhu
Chronic liver diseases caused by hepatitis B virus (HBV) are the accepted main cause leading to liver cirrhosis, hepatic fibrosis, and hepatic carcinoma. Sodium taurocholate cotransporting polypeptide (NTCP), a specific membrane receptor of hepatocytes for triggering HBV infection, is a promising target against HBV entry. In this study, pentacyclic triterpenoids (PTs) including glycyrrhetinic acid (GA), oleanolic acid (OA), ursolic acid (UA) and betulinic acid (BA) were modified via molecular hybridization with podophyllotoxin respectively, and resulted in thirty-two novel conjugates...
April 18, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38660644/hepatitis-b-virus-genotypes-in-precision-medicine-of-hepatitis-b-related-hepatocellular-carcinoma-where-we-are-now
#59
EDITORIAL
Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli
Hepatitis B virus (HBV) infection is a major player in chronic hepatitis B that may lead to the development of hepatocellular carcinoma (HCC). HBV genetics are diverse where it is classified into at least 9 genotypes (A to I) and 1 putative genotype (J), each with specific geographical distribution and possible different clinical outcomes in the patient. This diversity may be associated with the precision medicine for HBV-related HCC and the success of therapeutical approaches against HCC, related to different pathogenicity of the virus and host response...
April 15, 2024: World Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38660313/comparison-of-the-effectiveness-four-years-after-homo-hetero-prime-boost-with-10-%C3%AE-g-hp-and-20-%C3%AE-g-cho-recombinant-hepatitis-b-vaccine-at-1-and-6-months-in-maternal-hbsag-negative-children
#60
COMPARATIVE STUDY
Zhiying Yin, Tingcui Wen, Canya Fu, Junji Li, Quanjun Fang, Xiaoying Gong, Jialing You, Shuangqing Wang, Canjie Zheng
INTRODUCTION: Limited data were available on the effectivenessfour years after Homo or Hetero prime-boost with 10 μg Hansenulapolymorpha recombinant hepatitis B vaccine (HepB-HP) and 20 μgChinese hamster ovary cell HepB (HepB-CHO). METHODS: A crosssectional study was performed in maternalhepatitis B surface antigen (HBsAg)-negative children whoreceived one dose of 10 μg HepB-HP at birth, Homo or Heteroprime-boost with 10 μg HepB-HP and 20 μg HepB-CHO at 1 and 6months...
2024: Frontiers in Immunology
keyword
keyword
12171
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.